Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients Article Swipe
Takashi Oyama
,
Kazuhito Yamamoto
,
Naoko Asano
,
Aya Oshiro
,
Ritsuro Suzuki
,
Yoshitoyo Kagami
,
Yasuo Morishima
,
Kengo Takeuchi
,
Toshiyuki Izumo
,
Shigeo Mori
,
Koichi Ohshima
,
Junji Suzumiya
,
Naoya Nakamura
,
Masafumi Abe
,
Koichi Ichimura
,
Yumiko Sato
,
Tadashi Yoshino
,
Tomoki Naoe
,
Yoshie Shimoyama
,
Yoshikazu Kamiya
,
Tomohiro Kinoshita
,
Shigeo Nakamura
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6518005.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6518005.v1
Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients despite no predisposing immunodeficiency and were named as senile or age-related EBV+ B-cell LPDs. To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL).Experimental Design: Among 1,792 large B-cell LPD cases, 96 EBV+ cases with available clinical data set were enrolled for the present study. For the control group, 107 patients aged over 40 years with EBV-negative DLBCL were selected. We compared clinicopathologic data between two groups and determined prognostic factors by univariate and multivariate analysis.Results: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung. Overall survival was thus significantly inferior in age-related EBV+ group than in DLBCLs. Univariate and multivariate analyses further identified two factors, B symptoms and age older than 70 years, independently predictive for survival. A prognostic model using these two variables well defined three risk groups: low risk (no adverse factors), intermediate risk (one factor), and high risk (two factors).Conclusions: These findings suggest that age-related EBV+ B-cell LPDs constitute a distinct group, and innovative therapeutic strategies such as EBV-targeted T-cell therapy should be developed for this uncommon disease.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.c.6518005.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361958990
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361958990Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.c.6518005.v1Digital Object Identifier
- Title
-
Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 PatientsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Takashi Oyama, Kazuhito Yamamoto, Naoko Asano, Aya Oshiro, Ritsuro Suzuki, Yoshitoyo Kagami, Yasuo Morishima, Kengo Takeuchi, Toshiyuki Izumo, Shigeo Mori, Koichi Ohshima, Junji Suzumiya, Naoya Nakamura, Masafumi Abe, Koichi Ichimura, Yumiko Sato, Tadashi Yoshino, Tomoki Naoe, Yoshie Shimoyama, Yoshikazu Kamiya, Tomohiro Kinoshita, Shigeo NakamuraList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.c.6518005.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.c.6518005.v1Direct OA link when available
- Concepts
-
Internal medicine, Univariate analysis, Lymphoproliferative disorders, B cell, Medicine, Group B, Multivariate analysis, Immunology, Lymphoma, Epstein–Barr virus, Gastroenterology, Diffuse large B-cell lymphoma, Biology, Virus, AntibodyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361958990 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| ids.doi | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| ids.openalex | https://openalex.org/W4361958990 |
| fwci | |
| type | preprint |
| title | Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10685 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Viral-associated cancers and disorders |
| topics[1].id | https://openalex.org/T10185 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9968000054359436 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Lymphoma Diagnosis and Treatment |
| topics[2].id | https://openalex.org/T11157 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9922999739646912 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Chronic Lymphocytic Leukemia Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C126322002 |
| concepts[0].level | 1 |
| concepts[0].score | 0.6267427802085876 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[0].display_name | Internal medicine |
| concepts[1].id | https://openalex.org/C144301174 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6257658004760742 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7893852 |
| concepts[1].display_name | Univariate analysis |
| concepts[2].id | https://openalex.org/C2776995267 |
| concepts[2].level | 3 |
| concepts[2].score | 0.616248607635498 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q4165484 |
| concepts[2].display_name | Lymphoproliferative disorders |
| concepts[3].id | https://openalex.org/C2778453870 |
| concepts[3].level | 3 |
| concepts[3].score | 0.601438581943512 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q188930 |
| concepts[3].display_name | B cell |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.5198515057563782 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C2777785397 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4970429241657257 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q492194 |
| concepts[5].display_name | Group B |
| concepts[6].id | https://openalex.org/C38180746 |
| concepts[6].level | 2 |
| concepts[6].score | 0.48768675327301025 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1952580 |
| concepts[6].display_name | Multivariate analysis |
| concepts[7].id | https://openalex.org/C203014093 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4867272675037384 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[7].display_name | Immunology |
| concepts[8].id | https://openalex.org/C2779338263 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4798978567123413 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[8].display_name | Lymphoma |
| concepts[9].id | https://openalex.org/C2781375147 |
| concepts[9].level | 3 |
| concepts[9].score | 0.47104835510253906 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q6900 |
| concepts[9].display_name | Epstein–Barr virus |
| concepts[10].id | https://openalex.org/C90924648 |
| concepts[10].level | 1 |
| concepts[10].score | 0.4257677495479584 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[10].display_name | Gastroenterology |
| concepts[11].id | https://openalex.org/C2778559949 |
| concepts[11].level | 3 |
| concepts[11].score | 0.4227880835533142 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2626074 |
| concepts[11].display_name | Diffuse large B-cell lymphoma |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.3258248567581177 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C2522874641 |
| concepts[13].level | 2 |
| concepts[13].score | 0.2062358558177948 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q808 |
| concepts[13].display_name | Virus |
| concepts[14].id | https://openalex.org/C159654299 |
| concepts[14].level | 2 |
| concepts[14].score | 0.1509210765361786 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[14].display_name | Antibody |
| keywords[0].id | https://openalex.org/keywords/internal-medicine |
| keywords[0].score | 0.6267427802085876 |
| keywords[0].display_name | Internal medicine |
| keywords[1].id | https://openalex.org/keywords/univariate-analysis |
| keywords[1].score | 0.6257658004760742 |
| keywords[1].display_name | Univariate analysis |
| keywords[2].id | https://openalex.org/keywords/lymphoproliferative-disorders |
| keywords[2].score | 0.616248607635498 |
| keywords[2].display_name | Lymphoproliferative disorders |
| keywords[3].id | https://openalex.org/keywords/b-cell |
| keywords[3].score | 0.601438581943512 |
| keywords[3].display_name | B cell |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.5198515057563782 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/group-b |
| keywords[5].score | 0.4970429241657257 |
| keywords[5].display_name | Group B |
| keywords[6].id | https://openalex.org/keywords/multivariate-analysis |
| keywords[6].score | 0.48768675327301025 |
| keywords[6].display_name | Multivariate analysis |
| keywords[7].id | https://openalex.org/keywords/immunology |
| keywords[7].score | 0.4867272675037384 |
| keywords[7].display_name | Immunology |
| keywords[8].id | https://openalex.org/keywords/lymphoma |
| keywords[8].score | 0.4798978567123413 |
| keywords[8].display_name | Lymphoma |
| keywords[9].id | https://openalex.org/keywords/epstein–barr-virus |
| keywords[9].score | 0.47104835510253906 |
| keywords[9].display_name | Epstein–Barr virus |
| keywords[10].id | https://openalex.org/keywords/gastroenterology |
| keywords[10].score | 0.4257677495479584 |
| keywords[10].display_name | Gastroenterology |
| keywords[11].id | https://openalex.org/keywords/diffuse-large-b-cell-lymphoma |
| keywords[11].score | 0.4227880835533142 |
| keywords[11].display_name | Diffuse large B-cell lymphoma |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.3258248567581177 |
| keywords[12].display_name | Biology |
| keywords[13].id | https://openalex.org/keywords/virus |
| keywords[13].score | 0.2062358558177948 |
| keywords[13].display_name | Virus |
| keywords[14].id | https://openalex.org/keywords/antibody |
| keywords[14].score | 0.1509210765361786 |
| keywords[14].display_name | Antibody |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.c.6518005.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5042897532 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-8553-2975 |
| authorships[0].author.display_name | Takashi Oyama |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Takashi Oyama |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5018968800 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-8588-8955 |
| authorships[1].author.display_name | Kazuhito Yamamoto |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kazuhito Yamamoto |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5103203277 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-7536-6179 |
| authorships[2].author.display_name | Naoko Asano |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Naoko Asano |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5068805718 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Aya Oshiro |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Aya Oshiro |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5001596834 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5974-7614 |
| authorships[4].author.display_name | Ritsuro Suzuki |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Ritsuro Suzuki |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5049376343 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1566-3101 |
| authorships[5].author.display_name | Yoshitoyo Kagami |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Yoshitoyo Kagami |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5110696957 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Yasuo Morishima |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Yasuo Morishima |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5044544485 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-1599-5800 |
| authorships[7].author.display_name | Kengo Takeuchi |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kengo Takeuchi |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5042082981 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-8601-0434 |
| authorships[8].author.display_name | Toshiyuki Izumo |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Toshiyuki Izumo |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5111806627 |
| authorships[9].author.orcid | https://orcid.org/0009-0001-0392-9320 |
| authorships[9].author.display_name | Shigeo Mori |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Shigeo Mori |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5001399725 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-4996-5279 |
| authorships[10].author.display_name | Koichi Ohshima |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Koichi Ohshima |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5110133958 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Junji Suzumiya |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Junji Suzumiya |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5074064898 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-4332-5254 |
| authorships[12].author.display_name | Naoya Nakamura |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Naoya Nakamura |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5110794994 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Masafumi Abe |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Masafumi Abe |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5083342160 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-3851-2349 |
| authorships[14].author.display_name | Koichi Ichimura |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Koichi Ichimura |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5089849300 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Yumiko Sato |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Yumiko Sato |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5108362129 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Tadashi Yoshino |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Tadashi Yoshino |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5113454854 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Tomoki Naoe |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Tomoki Naoe |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5039206675 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | Yoshie Shimoyama |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Yoshie Shimoyama |
| authorships[18].is_corresponding | False |
| authorships[19].author.id | https://openalex.org/A5001354998 |
| authorships[19].author.orcid | https://orcid.org/0000-0002-5976-8626 |
| authorships[19].author.display_name | Yoshikazu Kamiya |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Yoshikazu Kamiya |
| authorships[19].is_corresponding | False |
| authorships[20].author.id | https://openalex.org/A5104110069 |
| authorships[20].author.orcid | |
| authorships[20].author.display_name | Tomohiro Kinoshita |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Tomohiro Kinoshita |
| authorships[20].is_corresponding | False |
| authorships[21].author.id | https://openalex.org/A5113553546 |
| authorships[21].author.orcid | |
| authorships[21].author.display_name | Shigeo Nakamura |
| authorships[21].author_position | last |
| authorships[21].raw_author_name | Shigeo Nakamura |
| authorships[21].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10685 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Viral-associated cancers and disorders |
| related_works | https://openalex.org/W4323822262, https://openalex.org/W3145575489, https://openalex.org/W2067780564, https://openalex.org/W2044155770, https://openalex.org/W2331691601, https://openalex.org/W2951008620, https://openalex.org/W2323865642, https://openalex.org/W2056530802, https://openalex.org/W1561888317, https://openalex.org/W2197052930 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.c.6518005.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| primary_location.id | doi:10.1158/1078-0432.c.6518005.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6518005.v1 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 190 |
| abstract_inverted_index.B | 148, 178 |
| abstract_inverted_index.a | 119, 225 |
| abstract_inverted_index.40 | 89 |
| abstract_inverted_index.70 | 184 |
| abstract_inverted_index.96 | 67 |
| abstract_inverted_index.To | 42 |
| abstract_inverted_index.We | 1, 96 |
| abstract_inverted_index.as | 35, 233 |
| abstract_inverted_index.be | 238 |
| abstract_inverted_index.by | 107 |
| abstract_inverted_index.in | 12, 23, 163, 168 |
| abstract_inverted_index.no | 29 |
| abstract_inverted_index.of | 18, 153 |
| abstract_inverted_index.or | 37, 127 |
| abstract_inverted_index.(no | 204 |
| abstract_inverted_index.107 | 85 |
| abstract_inverted_index.44% | 132 |
| abstract_inverted_index.49% | 146 |
| abstract_inverted_index.58% | 137 |
| abstract_inverted_index.For | 81 |
| abstract_inverted_index.LPD | 65 |
| abstract_inverted_index.age | 121, 181 |
| abstract_inverted_index.and | 32, 103, 109, 123, 150, 155, 171, 180, 211, 228 |
| abstract_inverted_index.for | 77, 188, 240 |
| abstract_inverted_index.low | 202 |
| abstract_inverted_index.set | 74 |
| abstract_inverted_index.the | 24, 78, 82 |
| abstract_inverted_index.two | 101, 176, 195 |
| abstract_inverted_index.was | 159 |
| abstract_inverted_index.(one | 209 |
| abstract_inverted_index.(two | 214 |
| abstract_inverted_index.EBV+ | 5, 19, 39, 48, 68, 115, 165, 221 |
| abstract_inverted_index.LPDs | 50, 117, 223 |
| abstract_inverted_index.aged | 87 |
| abstract_inverted_index.data | 73, 99 |
| abstract_inverted_index.have | 2 |
| abstract_inverted_index.high | 212 |
| abstract_inverted_index.over | 88 |
| abstract_inverted_index.risk | 200, 203, 208, 213 |
| abstract_inverted_index.skin | 154 |
| abstract_inverted_index.such | 232 |
| abstract_inverted_index.than | 129, 144, 167, 183 |
| abstract_inverted_index.that | 219 |
| abstract_inverted_index.this | 45, 241 |
| abstract_inverted_index.thus | 160 |
| abstract_inverted_index.well | 197 |
| abstract_inverted_index.were | 33, 51, 75, 94 |
| abstract_inverted_index.with | 53, 70, 91, 113, 133, 138, 147 |
| abstract_inverted_index.(LPD) | 9 |
| abstract_inverted_index.1,792 | 62 |
| abstract_inverted_index.Among | 61 |
| abstract_inverted_index.DLBCL | 93 |
| abstract_inverted_index.LPDs. | 41 |
| abstract_inverted_index.These | 216 |
| abstract_inverted_index.cases | 69 |
| abstract_inverted_index.group | 166 |
| abstract_inverted_index.large | 56, 63 |
| abstract_inverted_index.level | 142 |
| abstract_inverted_index.lung. | 156 |
| abstract_inverted_index.model | 192 |
| abstract_inverted_index.named | 34 |
| abstract_inverted_index.older | 182 |
| abstract_inverted_index.serum | 139 |
| abstract_inverted_index.these | 194 |
| abstract_inverted_index.three | 199 |
| abstract_inverted_index.using | 193 |
| abstract_inverted_index.which | 15 |
| abstract_inverted_index.years | 90 |
| abstract_inverted_index.>1, | 136 |
| abstract_inverted_index.B-cell | 6, 20, 40, 49, 57, 64, 116, 222 |
| abstract_inverted_index.T-cell | 235 |
| abstract_inverted_index.cases, | 66 |
| abstract_inverted_index.group, | 84, 227 |
| abstract_inverted_index.groups | 102 |
| abstract_inverted_index.higher | 120, 143, 151 |
| abstract_inverted_index.senile | 36 |
| abstract_inverted_index.shared | 16 |
| abstract_inverted_index.should | 237 |
| abstract_inverted_index.showed | 118 |
| abstract_inverted_index.status | 135 |
| abstract_inverted_index.study. | 80 |
| abstract_inverted_index.years, | 185 |
| abstract_inverted_index.DLBCLs. | 169 |
| abstract_inverted_index.DLBCLs: | 131 |
| abstract_inverted_index.Overall | 157 |
| abstract_inverted_index.adverse | 205 |
| abstract_inverted_index.arising | 22 |
| abstract_inverted_index.between | 100 |
| abstract_inverted_index.control | 83 |
| abstract_inverted_index.defined | 198 |
| abstract_inverted_index.despite | 28 |
| abstract_inverted_index.diffuse | 55 |
| abstract_inverted_index.elderly | 13 |
| abstract_inverted_index.factors | 106 |
| abstract_inverted_index.further | 43, 174 |
| abstract_inverted_index.groups: | 201 |
| abstract_inverted_index.lactate | 140 |
| abstract_inverted_index.normal, | 145 |
| abstract_inverted_index.present | 79 |
| abstract_inverted_index.suggest | 218 |
| abstract_inverted_index.therapy | 236 |
| abstract_inverted_index.Patients | 112 |
| abstract_inverted_index.analyses | 173 |
| abstract_inverted_index.clinical | 72, 125 |
| abstract_inverted_index.compared | 52, 97 |
| abstract_inverted_index.disease, | 46 |
| abstract_inverted_index.distinct | 226 |
| abstract_inverted_index.enrolled | 76 |
| abstract_inverted_index.factor), | 210 |
| abstract_inverted_index.factors, | 177 |
| abstract_inverted_index.features | 17, 126 |
| abstract_inverted_index.findings | 217 |
| abstract_inverted_index.inferior | 162 |
| abstract_inverted_index.patients | 27, 86 |
| abstract_inverted_index.recently | 3 |
| abstract_inverted_index.reported | 4 |
| abstract_inverted_index.survival | 158 |
| abstract_inverted_index.symptoms | 179 |
| abstract_inverted_index.uncommon | 242 |
| abstract_inverted_index.available | 71 |
| abstract_inverted_index.developed | 239 |
| abstract_inverted_index.disorders | 8 |
| abstract_inverted_index.factors), | 206 |
| abstract_inverted_index.lymphomas | 58 |
| abstract_inverted_index.neoplasms | 21 |
| abstract_inverted_index.occurring | 10 |
| abstract_inverted_index.patients, | 14 |
| abstract_inverted_index.selected. | 95 |
| abstract_inverted_index.survival. | 189 |
| abstract_inverted_index.symptoms, | 149 |
| abstract_inverted_index.variables | 196 |
| abstract_inverted_index.Univariate | 170 |
| abstract_inverted_index.aggressive | 124 |
| abstract_inverted_index.constitute | 224 |
| abstract_inverted_index.determined | 104 |
| abstract_inverted_index.identified | 175 |
| abstract_inverted_index.innovative | 229 |
| abstract_inverted_index.parameters | 128 |
| abstract_inverted_index.predictive | 187 |
| abstract_inverted_index.prognostic | 105, 191 |
| abstract_inverted_index.strategies | 231 |
| abstract_inverted_index.univariate | 108 |
| abstract_inverted_index.age-related | 38, 47, 114, 164, 220 |
| abstract_inverted_index.involvement | 152 |
| abstract_inverted_index.performance | 134 |
| abstract_inverted_index.therapeutic | 230 |
| abstract_inverted_index.EBV-negative | 54, 92, 130 |
| abstract_inverted_index.EBV-targeted | 234 |
| abstract_inverted_index.characterize | 44 |
| abstract_inverted_index.deteriorated | 26 |
| abstract_inverted_index.distribution | 122 |
| abstract_inverted_index.intermediate | 207 |
| abstract_inverted_index.multivariate | 110, 172 |
| abstract_inverted_index.predisposing | 30 |
| abstract_inverted_index.dehydrogenase | 141 |
| abstract_inverted_index.independently | 186 |
| abstract_inverted_index.predominantly | 11 |
| abstract_inverted_index.significantly | 161 |
| abstract_inverted_index.immunologically | 25 |
| abstract_inverted_index.immunodeficiency | 31 |
| abstract_inverted_index.Design:</b> | 60 |
| abstract_inverted_index.clinicopathologic | 98 |
| abstract_inverted_index.lymphoproliferative | 7 |
| abstract_inverted_index.disease.</p></div> | 243 |
| abstract_inverted_index.(DLBCL).</p><p><b>Experimental | 59 |
| abstract_inverted_index.<div>Abstract<p><b>Purpose:</b> | 0 |
| abstract_inverted_index.analysis.</p><p><b>Results:</b> | 111 |
| abstract_inverted_index.factors).</p><p><b>Conclusions:</b> | 215 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 22 |
| citation_normalized_percentile.value | 0.18981386 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |